Mario Maldonado
Basel, BS 4057, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 14, 2025
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
Journal: European journal of endocrinology
Published: April 25, 2014
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 16, 2014
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Journal: Clinical endocrinology
Published: September 27, 2013
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Journal: Pituitary
Published: August 15, 2013
Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
Journal: The patient
Published: April 12, 2013
High variability in baseline urinary free cortisol values in patients with Cushing's disease.
Journal: Clinical endocrinology
Published: March 06, 2013
A 12-month phase 3 study of pasireotide in Cushing's disease.
Journal: The New England journal of medicine
Published: March 09, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026